Taxotere Improves Survival in Advanced Prostate Cancer

by Medindia Content Team on  February 28, 2007 at 6:38 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Taxotere Improves Survival in Advanced Prostate Cancer
Sanofi-Aventis, one of the world's leading pharmaceutical companies, issued a press release that stated Taxotere (docetaxel) improves survival in patients with metastatic prostate cancer.

A Phase III clinical trial named TAX 327 compared Taxotere plus prednisone to Novantrone (mitoxantrone) plus prednisone. The study included a little over a thousand men who had recurrences or spread of disease after hormonal therapy.

The results of the study showed that survival was improved by 21 percent among patients treated with the Taxotere based therapy. The men also were without pain for a longer periods of time than those treated with Novantrone based therapy.

Researchers conclude that these long term results continue to provide evidence that Taxotere based therapy improves survival for advanced prostate cancer patients.

Source: Bio-Bio Technology
SRM

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Hematuria Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Medical Management of Prostate Cancer 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive